share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股sec公告 ·  07/02 19:09
牛牛AI助理已提取核心訊息
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
On July 2, 2024, Ardelyx, Inc., a biopharmaceutical company, announced its decision not to seek inclusion of its drug XPHOZAH (tenapanor) in the CMS ESRD PPS TDAPA. This decision was made to maintain patient access to XPHOZAH, which is a phosphate absorption inhibitor used in the treatment of patients with end-stage renal disease. The announcement was made in a Form 8-K filing with the SEC. Ardelyx, which is traded on the Nasdaq Global Market under the symbol ARDX, did not provide further details on the implications of this decision or any alternative strategies it might pursue.
2024年7月2日，生物製藥公司Ardelyx宣佈決定不在CMS ESRD PPS TDAPA中尋求其藥物XPHOZAH（tenapanor）的納入。此決定是爲了維護患者對耐受性腎病患者治療中使用的磷酸吸收抑制劑XPHOZAH的訪問權。該公告是通過向SEC提交8-K表格來發布的。Ardelyx在納斯達克全球市場上交易，股票代號是ARDX，未透露任何此決定的影響或其可能採取的其他策略的詳細信息。
2024年7月2日，生物製藥公司Ardelyx宣佈決定不在CMS ESRD PPS TDAPA中尋求其藥物XPHOZAH（tenapanor）的納入。此決定是爲了維護患者對耐受性腎病患者治療中使用的磷酸吸收抑制劑XPHOZAH的訪問權。該公告是通過向SEC提交8-K表格來發布的。Ardelyx在納斯達克全球市場上交易，股票代號是ARDX，未透露任何此決定的影響或其可能採取的其他策略的詳細信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。